Medical Devices · Acton, Massachusetts, United States
$156.52
+0.07% (+$0.11)2026-07-09
Smart-Money SignalDistribution · 41/100— Insiders are net buyers over 90 days ($674K, 6 buys vs 2 sales)
Revenue$761.7M
Net Income$91.1M
EPS$1.30
Gross Margin69.5%
Market Cap$10.8B
Price Performance
Historical data including institutional events
Company Profile
A
Ashley McEvoy
CEO & Executive Director
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally.
The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System.
It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy.
The company sells its products to end-users through the pharmacy channel; and independent distributors.
Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.